Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PVLA Palvella Therapeutics

Closed Independence Day 07-02 16:00:00 EDT

146.76

+8.50

+6.15%

盘后146.76

+0.000.00%

19:15 EDT

High146.88	Low136.77	Vol321.85K
Open138.58	D1 Closing138.26	Amplitude7.31%
Mkt Cap2.10B	Tradable Cap1.23B	Total Shares14.31M
T/O45.92M	T/O Rate3.83%	Tradable Shares8.40M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":146.76,"timestamp":1783022400000,"preClose":138.26,"halted":0,"volume":321853,"hourTrading":{"tag":"盘后","latestPrice":146.76,"preClose":146.76,"latestTime":"19:15 EDT","volume":70,"amount":10274.61,"timestamp":1783034156100,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.061478374077824395,"floatShares":8398100,"shares":14313699,"eps":-4.188664,"marketStatus":"Closed Independence Day","change":8.5,"latestTime":"07-02 16:00:00 EDT","open":138.58,"high":146.88,"low":136.77,"amount":45922027.88089,"amplitude":0.073123,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.188664,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":138.26,"postHourTrading":{"tag":"盘后","latestPrice":146.76,"preClose":146.76,"latestTime":"19:15 EDT","volume":70,"amount":10274.61,"timestamp":1783034156100,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.594248,"impliedVol":0.5745,"impliedVolPercentile":0.1594},"requestUrl":"/m/hq/s/PVLA/wiki","defaultTab":"wiki","newsList":[{"id":"2648269525","title":"Palvella Therapeutics Director Matthew Pauls Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2648269525","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648269525?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:06","pubTimestamp":1782936379,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics director Matthew Pauls files initial beneficial ownership statementPalvella Therapeutics director Matthew Pauls filed an initial Form 3 on June 29.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL5nftkl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648511774","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648511774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648511774?lang=en_us&edition=fundamental","pubTime":"2026-07-01 17:50","pubTimestamp":1782899413,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Techne (TECH), Concentra Group Holdings Parent...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bio-techne-tech-concentra-group-holdings-parent-inc-con-and-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bio-techne-tech-concentra-group-holdings-parent-inc-con-and-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4581","IE00B64QTZ34.USD","LU0029874061.USD","BK4588","IE0034390439.USD","HCSG","BK4121","LU0128526141.USD","TECH","PVLA","IE00B19Z6F94.USD","LU2237957902.USD","LU2237957811.SGD","BK4137","BK4185","BK4139","CON","XBI","XLV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553761","title":"Palvella Therapeutics Adds Industry Veteran to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553761","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553761?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:58","pubTimestamp":1782820708,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Palvella Therapeutics ( ($PVLA) ). On June 29, 2026, Palvella Therapeutics, Inc. expanded its Board of Director...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-adds-industry-veteran-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-adds-industry-veteran-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558911","title":"Palvella Therapeutics Appoints Savara CEO Matt Pauls to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558911","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558911?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:31","pubTimestamp":1782819065,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics appoints Savara CEO Matt Pauls to board of directorsPalvella Therapeutics appointed Matt Pauls to its board as it prepares for a potential US launch of QTORIN rapamycin.Pauls is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL9zc8Wg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","SG9999014005.SGD","BK4112","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BN0W2T93.GBP","BK4139","SG9999014021.USD","PVLA","BK4585","BK4588","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BKPKM429.USD","BK4007","XERS","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558930","title":"Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.d., M.b.a., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558930","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558930?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:30","pubTimestamp":1782819001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUAB4TMLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647791073","title":"Palvella submits first rolling new drug application to FDA for Qtorin","url":"https://stock-news.laohu8.com/highlight/detail?id=2647791073","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647791073?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:55","pubTimestamp":1782734132,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced that the company has submitted the first module of its rolling new drug application, or NDA, to the FDA seek...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-submits-first-rolling-new-drug-application-to-fda-for-qtorin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-submits-first-rolling-new-drug-application-to-fda-for-qtorin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","LABU","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647376149","title":"Palvella Submits First NDA Module to FDA for Qtorin Rapamycin Under Rolling Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2647376149","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647376149?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732643,"startTime":"0","endTime":"0","summary":"Palvella submits first NDA module to FDA for QTORIN rapamycin under rolling reviewPalvella began a rolling FDA New Drug Application for QTORIN 3.9% rapamycin gel to treat microcystic lymphatic malform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL1JNKN7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2T93.GBP","BK4112","BK4588","SG9999014021.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014013.SGD","BK4139","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2W23.USD","NDAQ","PVLA","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2095319765.USD","LU0314104364.USD","SG9999014005.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647769093","title":"Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2647769093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647769093?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA8YVMRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647761883","title":"Palvella Therapeutics - Expects to Complete Nda Submission in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647761883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647761883?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA8YVMRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645989763","title":"Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645989763","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645989763?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:20","pubTimestamp":1782300049,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA), Verastem (VSTM) and Ar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-verastem-vstm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-verastem-vstm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645008393","title":"Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2645008393","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645008393?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:07","pubTimestamp":1782162426,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics COO Kathleen Goin sold 4,302 common shares on June 17, 2026 at about $110.72 to $112.23.Sales followed option exercises for 4,302 shares at $7.14 to $9.08.Goin’s direct common stock holdings fell to zero.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL975DWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645607859","title":"Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645607859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645607859?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:45","pubTimestamp":1782135943,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Albert Lowe reiterated a Buy rating on Palvella Therapeutics today and set a price target of $205.00. According to TipRanks, L...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022550","title":"Palvella Therapeutics' Qtorin Granted FDA Rolling Review; Shares Rise Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022550","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022550?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:26","pubTimestamp":1782131161,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) said Monday that the US Food and Drug Administration has granted rolling review for its New Drug Application for Qtorin rapamycin to treat microcystic lymphatic malformati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4588","PVLA","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645246980","title":"FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2645246980","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645246980?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:56","pubTimestamp":1782129389,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced today that FDA has granted rolling review for the company’s new drug application, or NDA, for Qtorin rapamyc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-grants-rolling-review-to-palvella-therapeutics-qtorin-rapamycin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-grants-rolling-review-to-palvella-therapeutics-qtorin-rapamycin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","BK4585","PVLA","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021189","title":"FDA grants rolling review for Palvella QTORIN rapamycin NDA in microcystic lymphatic malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021189","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645021189?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:30","pubTimestamp":1782127826,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics received FDA rolling review for its QTORIN rapamycin NDA in microcystic lymphatic malformations.NDA submission remains targeted for the second half of 2026.Program holds FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL5Q2nBt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4588","SG9999014013.SGD","SG9999014005.SGD","BK4112","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","BK4585","BK4139","SG9999014021.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645995021","title":"FDA Grants Rolling Review of Palvella’s Qtorin™ Rapamycin Nda for Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2645995021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645995021?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:30","pubTimestamp":1782127800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2W96SK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021973","title":"Palvella Therapeutics - to Complete Qtorin Rapamycin Nda Submission in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645021973?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:30","pubTimestamp":1782127800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2W96SK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643024643","title":"Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643024643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643024643?lang=en_us&edition=fundamental","pubTime":"2026-06-14 16:50","pubTimestamp":1781427005,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Palvella Therapeutics (PVLA) with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-biogen-biib-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-biogen-biib-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","LU0234570918.USD","BK4139","BK4532","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4533","BK4585","BIIB","LU0320765992.SGD","LU0889565916.HKD","BK4588","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640420163","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2640420163","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640420163?lang=en_us&edition=fundamental","pubTime":"2026-06-04 22:21","pubTimestamp":1780582910,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA), Perspective Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-207?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-207?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640490178","title":"Palvella Therapeutics Says No Additional Efficacy Study Planned for Qtorin Rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2640490178","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640490178?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:17","pubTimestamp":1780489028,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics  said Wednesday that no additional efficacy study has been planned for Qtorin rapamycin in microcystic lymphatic malformations to support the planned submission of a new drug application in H2.The company said that based on the minutes of its pre-NDA meeting with the US Food and Drug Administration, the planned filing would be supported by the existing evidence package.The evidence package will include efficacy and safety results from a phase 3 trial, data from a phase 2 study used as basis for Qtorin rapamycin's breakthrough therapy designation, as well as real-world evidence from published literature and clinical experience with off-label rapamycin in microcystic lymphatic malformations, according to the company.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":0.0775},{"period":"1month","weight":0.4021},{"period":"3month","weight":0.1887},{"period":"6month","weight":0.4635},{"period":"1year","weight":5.1599},{"period":"ytd","weight":0.4021}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.069248},{"month":2,"riseRate":0.545455,"avgChangeRate":0.088954},{"month":3,"riseRate":0.454545,"avgChangeRate":0.004194},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.071975},{"month":5,"riseRate":0.454545,"avgChangeRate":0.145935},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.054496},{"month":7,"riseRate":0.666667,"avgChangeRate":0.152247},{"month":8,"riseRate":0.636364,"avgChangeRate":0.117993},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.090465},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.050324},{"month":11,"riseRate":0.545455,"avgChangeRate":0.066832},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.051298}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction